LIR Life Sciences signs development services agreement with Oxygen Handel for transdermal obesity pipeline roadmap

• LIR Life Sciences signed a development services agreement with Oxygen Handel GmbH to build an FDA-focused regulatory and preclinical roadmap for its transdermal obesity pipeline.
• Work targets transdermal GLP-1 and GLP/GIP candidates, including evaluation of a potential 505(b)(2) pathway and bridging to approved molecules.
• Phase 0 planning will set development milestones, sequencing, risk analysis, and budget forecasts to guide future regulatory engagement and commercialization planning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lir Life Sciences Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607161800ACCESSWRNAPR_____1192042) on July 16, 2026, and is solely responsible for the information contained therein.